Literature DB >> 14981079

Cyclic AMP-dependent protein kinase phosphorylates merlin at serine 518 independently of p21-activated kinase and promotes merlin-ezrin heterodimerization.

Kaija Alfthan1, Leena Heiska, Mikaela Grönholm, G Herma Renkema, Olli Carpén.   

Abstract

Mutations in the NF2 tumor suppressor gene encoding merlin induce the development of tumors of the nervous system. Merlin is highly homologous to the ERM (ezrin-radixin-moesin) family of membrane/cytoskeleton linker proteins. However, the mechanism for the tumor suppressing activity of merlin is not well understood. Previously, we characterized a novel role for merlin as a protein kinase A (PKA)-anchoring protein, which links merlin to the cAMP/PKA signaling pathway. In this study we show that merlin is also a target for PKA-induced phosphorylation. In vitro [gamma-(33)P]ATP labeling revealed that both the merlin N and C termini are phosphorylated by PKA. Furthermore, both in vitro and in vivo phosphorylation studies of the wild-type and mutated C termini demonstrated that PKA can phosphorylate merlin at serine 518, a site that is phosphorylated also by p21-activated kinases (PAKs). Merlin was phosphorylated by PKA in cells in which PAK activity was suppressed, indicating that the two kinases function independently. Both in vitro and in vivo interaction studies indicated that phosphorylation of serine 518 promotes heterodimerization between merlin and ezrin, an event suggested to convert merlin from a growth-suppressive to a growth-permissive state. This study provides further evidence on the connection between merlin and cAMP/PKA signaling and suggests a role for merlin in the cAMP/PKA transduction pathway.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14981079     DOI: 10.1074/jbc.M313916200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  50 in total

Review 1.  Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms.

Authors:  Steven L Carroll
Journal:  Acta Neuropathol       Date:  2011-12-11       Impact factor: 17.088

Review 2.  Merlin: a tumour suppressor with functions at the cell cortex and in the nucleus.

Authors:  Wei Li; Jonathan Cooper; Matthias A Karajannis; Filippo G Giancotti
Journal:  EMBO Rep       Date:  2012-03       Impact factor: 8.807

3.  Schwannomin/merlin promotes Schwann cell elongation and influences myelin segment length.

Authors:  Courtney Thaxton; Marga Bott; Barbara Walker; Nicklaus A Sparrow; Stephen Lambert; Cristina Fernandez-Valle
Journal:  Mol Cell Neurosci       Date:  2010-12-21       Impact factor: 4.314

4.  Akt2 phosphorylates ezrin to trigger NHE3 translocation and activation.

Authors:  Harn Shiue; Mark W Musch; Yingmin Wang; Eugene B Chang; Jerrold R Turner
Journal:  J Biol Chem       Date:  2004-11-04       Impact factor: 5.157

5.  Multistep phosphorylation by oncogenic kinases enhances the degradation of the NF2 tumor suppressor merlin.

Authors:  Minja Laulajainen; Taru Muranen; Tuula A Nyman; Olli Carpén; Mikaela Grönholm
Journal:  Neoplasia       Date:  2011-07       Impact factor: 5.715

Review 6.  Neurofibromatosis type 2.

Authors:  Ashok R Asthagiri; Dilys M Parry; John A Butman; H Jeffrey Kim; Ekaterini T Tsilou; Zhengping Zhuang; Russell R Lonser
Journal:  Lancet       Date:  2009-05-22       Impact factor: 79.321

7.  Unfurling of the band 4.1, ezrin, radixin, moesin (FERM) domain of the merlin tumor suppressor.

Authors:  S D Yogesha; Andrew J Sharff; Marco Giovannini; Gerard Bricogne; Tina Izard
Journal:  Protein Sci       Date:  2011-11-09       Impact factor: 6.725

8.  Loss of NF2/Merlin expression in advanced sporadic colorectal cancer.

Authors:  Tamara Cačev; Gorana Aralica; Božo Lončar; Sanja Kapitanović
Journal:  Cell Oncol (Dordr)       Date:  2013-12-10       Impact factor: 6.730

9.  Tissue-specific ablation of Prkar1a causes schwannomas by suppressing neurofibromatosis protein production.

Authors:  Georgette N Jones; Chhavy Tep; William H Towns; Georgeta Mihai; Ian D Tonks; Graham F Kay; Petra M Schmalbrock; Anat O Stemmer-Rachamimov; Sung Ok Yoon; Lawrence S Kirschner
Journal:  Neoplasia       Date:  2008-11       Impact factor: 5.715

10.  Validation of the p21-activated kinases as targets for inhibition in neurofibromatosis type 2.

Authors:  Chunling Yi; Erik W Wilker; Michael B Yaffe; Anat Stemmer-Rachamimov; Joseph L Kissil
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.